Immunome (NASDAQ:IMNM) Sets New 12-Month High - Should You Buy?Market Beat·Aug 19 at 10:00 AMIMNM+4.64%
Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 10,125 SharesMarket Beat·Aug 12 at 06:22 PMIMNM+4.64%BLK+0.19%
Immunome director Isaac Barchas reports disposal of common shares worth $2.18 millionPUBT·Aug 12 at 04:48 PMIMNM+4.64%
Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update | IMNM Stock NewsStockTitan·Aug 11 at 07:02 AMIMNM+4.64%
Immunome (IMNM) Starts IM 3050 Trial As Valuation Questions Come Into ViewSimplywall·Aug 11 at 02:39 AMIMNM+4.64%
Immunome director Isaac Barchas reports disposal of 36,088 common shares worth $940,453.28PUBT·Aug 10 at 03:11 PMIMNM+4.64%
Immunome Chief Business Officer Horn Kinney sells 90,616 common shares for $2.27 millionPUBT·Aug 6 at 05:36 PMIMNM+4.64%
Immunome grants inducement stock options for 176,500 shares at $23.01 to new hiresPUBT·Aug 6 at 03:17 PMIMNM+4.64%
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors | IMNM Stock NewsStockTitan·Jul 19 at 10:30 PMIMNM+4.64%
